NASDAQ Composite ended the session with Amicus Therapeutics jumping 4.47% to $10.28 on Monday while nASDAQ Composite fell 0.48% to $13,895.12.

Amicus Therapeutics today’s close was $10.28, 146.98% below its 52-week high of $25.39.

Amicus Therapeutics’s Sales

Amicus Therapeutics’s sales growth is 18.4% for the current quarter and 20.6% for the next. The company’s growth estimates for the ongoing quarter is 31.4% and a drop 10% for the next.

Amicus Therapeutics’s Revenue

Year-on-year quarterly revenue growth grew by 27.6%, now sitting on 260.89M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Amicus Therapeutics’s stock is considered to be overbought (>=80).

Amicus Therapeutics’s Stock Yearly Top and Bottom Value

Amicus Therapeutics’s stock is valued at $10.28 at 17:33 EST, way under its 52-week high of $25.39 and way above its 52-week low of $8.83.

Amicus Therapeutics’s Moving Average

Amicus Therapeutics’s worth is below its 50-day moving average of $10.76 and way under its 200-day moving average of $17.69.

More news about Amicus Therapeutics.

LEAVE A REPLY

Please enter your comment!
Please enter your name here